Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.84 |
| ▸ | BRD2 | P25440 | 18/20 | 0.84 |
| ▸ | BRD3 | Q15059 | 17/20 | 0.84 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | TAF1 | P21675 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | EP300 | Q09472 | 1/20 | 0.82 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.82 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.82 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.82 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.82 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.82 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225867 | 1.00 | BRD4 (0.84) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5836648 | 0.92 | BRD4 (0.75) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5836642 | 0.92 | BRD4 (0.75) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5836637 | 0.92 | BRD4 (0.75) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL26487445 | 0.91 | BRD4 (0.84) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL19985767 | 0.91 | BRD4 (0.87) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL11908462 | 0.91 | BRD4 (0.77) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL11978849 | 0.91 | BRD4 (0.77) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL1902624 | 0.91 | BRD4 (0.77) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL11978890 | 0.91 | BRD4 (0.77) | BRD4BRD2BRD3TRIM24CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 864 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102387-A1 | IMMUNOSUPPRESSIVE COMPOUNDS | UNIV BASEL (CH) | 2026-04-16 | — | — | US | claimed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | claimed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4605088-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2025-08-27 | — | — | EP | claimed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | claimed |
| EP-4594304-A2 | IMMUNOSUPPRESSIVE COMPOUNDS | Universität Basel Vizerektorat Forschung (CH) | 2025-08-06 | — | — | EP | claimed |
| CN-120202189-A | Immunosuppressant compounds | 巴塞尔大学 | 2025-06-24 | — | — | CN | claimed |
| CN-112533620-B | Treatment of tumors by combination of oncolytic adenoviruses and CDK4/6 inhibitors | 慕尼黑工业大学临床教学中心 | 2025-03-28 | — | — | CN | claimed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2022184664-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-09-09 | — | — | WO | claimed |
| WO-2022187611-A1 | CDK INHIBITOR COMPOUNDS FOR USE IN METHODS OF TREATMENT | LIFEMINE THERAPEUTICS (US) | 2022-09-09 | — | — | WO | claimed |
| US-20220202814-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | claimed |
| US-20220117942-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | ZENITH EPIGENETICS LTD. (CA) | 2022-04-21 | — | — | US | claimed |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-03-24 | — | — | US | claimed |
| US-20220089576-A1 | ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS | LINNAEUS THERAPEUTICS INC (US) | 2022-03-24 | — | — | US | claimed |
| WO-2022054625-A1 | PYRROLE-IMIDAZOLE POLYAMIDE HAVING IMPROVED NUCLEAR TRANSPORTATION PROPERTIES | 国立大学法人京都大学 | 2022-03-17 | — | — | WO | claimed |
| US-20220062246-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | ZENITH EPIGENETICS LTD. (CA) | 2022-03-03 | — | — | US | claimed |
| US-20220047563-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | ZENITH EPIGENETICS LTD (CA) | 2022-02-17 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | BRD4 3/4885BRD2 9/4885BRD3 4/4885 |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | NSUN2, IRF3, DNMT3B | BRD4 1063/4885BRD2 989/4885BRD3 426/4885 |
| US-20220202814-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | BRD4 769/4885BRD2 2010/4885BRD3 1079/4885 |
| US-20220062246-A1 | COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | BRD4, PARP1, BRD3 | BRD4 1/4885BRD2 6/4885BRD3 3/4885 |
| US-20220089576-A1 | ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS | GPER1, GPBAR1, GPR3 | BRD4 3595/4885BRD2 4215/4885BRD3 3823/4885 |
| US-20220117942-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER | BRDT, BRD4, BRPF3 | BRD4 2/4885BRD2 6/4885BRD3 4/4885 |
| US-20220047563-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER | CDK4, CDK6, BRD4 | BRD4 3/4885BRD2 7/4885BRD3 8/4885 |
| US-20260102387-A1 | IMMUNOSUPPRESSIVE COMPOUNDS | CHP1, BRD3, IRF3 | BRD4 95/4885BRD2 22/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.